Search research articles
Contact Us
Filters
Showing results (91-100 of 148) with videos related to
Page
of 15
Sort By:
Journal of Medicinal Chemistry
|
December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
R J Griffin, S Srinivasan, K Bowman, et al.
British Journal of Cancer
|
January 1, 1997
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines
E J Estlin, K Balmanno, A H Calvert, et al.
Seminars in Oncology
|
October 1, 1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions
A H Calvert, A Boddy, N P Bailey, et al.
British Journal of Cancer
|
February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277
B J Foster, D R Newell, J Carmichael, et al.
Cancer Treatment Reports
|
August 1, 1986
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse
D R Newell, D L Alison, A H Calvert, et al.
British Journal of Cancer
|
January 7, 2010
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
J E Nutt, A R A Razak, K O'Toole, et al.
British Journal of Cancer
|
May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel
A N Hughes, M J Griffin, D R Newell, et al.
Biochemical Pharmacology
|
October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
A L Jackman, D R Newell, W Gibson, et al.
Journal of Medicinal Chemistry
|
March 1, 1989
Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position
P R Marsham, P Chambers, A J Hayter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2003
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
G Atalay, L Biganzoli, F Renard, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 148) with videos related to
Sort By:
Page
of 15
Journal of Medicinal Chemistry
|
December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
R J Griffin, S Srinivasan, K Bowman, et al.
British Journal of Cancer
|
January 1, 1997
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines
E J Estlin, K Balmanno, A H Calvert, et al.
Seminars in Oncology
|
October 1, 1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions
A H Calvert, A Boddy, N P Bailey, et al.
British Journal of Cancer
|
February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277
B J Foster, D R Newell, J Carmichael, et al.
Cancer Treatment Reports
|
August 1, 1986
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse
D R Newell, D L Alison, A H Calvert, et al.
British Journal of Cancer
|
January 7, 2010
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
J E Nutt, A R A Razak, K O'Toole, et al.
British Journal of Cancer
|
May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel
A N Hughes, M J Griffin, D R Newell, et al.
Biochemical Pharmacology
|
October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
A L Jackman, D R Newell, W Gibson, et al.
Journal of Medicinal Chemistry
|
March 1, 1989
Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position
P R Marsham, P Chambers, A J Hayter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2003
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
G Atalay, L Biganzoli, F Renard, et al.
Page
of 15